[Reevaluation of penicillin allergy labeling, appropriate use of β-lactam antibiotics, and multidrug resistance].

IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Medicina-buenos Aires Pub Date : 2024-01-01
Emilio F Huaier Arriazu, Corina Nemirovsky, Liliana O Clara
{"title":"[Reevaluation of penicillin allergy labeling, appropriate use of β-lactam antibiotics, and multidrug resistance].","authors":"Emilio F Huaier Arriazu, Corina Nemirovsky, Liliana O Clara","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Approximately 10% of the population reports being allergic to penicillin, although usually less than 1% really are. In addition, people with proven allergies over the years may no longer be allergic. Unconfirmed penicillin allergy and use of alternative antimicrobials result in more treatment failures; more severe adverse effects. Higher cost; longer hospitalizations; increase in the emergence of multi-resistant germs associated with health care. The risk of cross-allergy between β-lactam groups is usually <2%, depending on the similarity of the side chains, so prescribing antibiotics from another β-lactam group is safe as long as we take into account the structural similarity. Incorporating the reassessment of allergies and improving the prescription of antibiotics in this group of patients reduces the generation and spread of multi-resistant germs, and the associated costs. There are simple methods and specific scores that simplify allergy reassessment. The objective of this review is to expose how, through these methods, the delabeling of patients erroneously labeled as allergic and the safe prescription of β-lactam antibiotics can be achieved.</p>","PeriodicalId":18419,"journal":{"name":"Medicina-buenos Aires","volume":"84 5","pages":"946-958"},"PeriodicalIF":0.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina-buenos Aires","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Approximately 10% of the population reports being allergic to penicillin, although usually less than 1% really are. In addition, people with proven allergies over the years may no longer be allergic. Unconfirmed penicillin allergy and use of alternative antimicrobials result in more treatment failures; more severe adverse effects. Higher cost; longer hospitalizations; increase in the emergence of multi-resistant germs associated with health care. The risk of cross-allergy between β-lactam groups is usually <2%, depending on the similarity of the side chains, so prescribing antibiotics from another β-lactam group is safe as long as we take into account the structural similarity. Incorporating the reassessment of allergies and improving the prescription of antibiotics in this group of patients reduces the generation and spread of multi-resistant germs, and the associated costs. There are simple methods and specific scores that simplify allergy reassessment. The objective of this review is to expose how, through these methods, the delabeling of patients erroneously labeled as allergic and the safe prescription of β-lactam antibiotics can be achieved.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[重新评估青霉素过敏标签、β-内酰胺类抗生素的合理使用和多药耐药性]。
大约有 10%的人表示对青霉素过敏,但真正过敏的人通常不到 1%。此外,多年来被证实过敏的人可能不再过敏。未经证实的青霉素过敏和使用替代抗菌药会导致更多的治疗失败;更严重的不良反应。成本更高;住院时间更长;与医疗保健相关的多重耐药病菌增多。β-内酰胺类之间发生交叉过敏的风险通常是
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Medicina-buenos Aires
Medicina-buenos Aires 医学-医学:内科
CiteScore
1.30
自引率
12.50%
发文量
0
审稿时长
6-12 weeks
期刊介绍: Information not localized
期刊最新文献
[Clinical approach to the patient with obesity document by the Argentine Society of Medicine, the Uruguayan Society of Internal Medicine, and the International Forum of Internal Medicine]. JOINT MEETING SAIC SAFIS ALACF 2024. Joint Meeting SAIC SAFIS ALACF 2024. [Angelman syndrome: current approach and the future of therapies]. [Autism: associated medical conditions].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1